Icon
+91 94997 68112
Login Register

Corlanor - (5, 7.5 mg; Tablet, Oral)

Ivabradine Hydrochloride Amgen
5, 7.5 mg; Tablet, Oral
Less Than $1000 mn
More Than 5
More Than 5
More Than 5
Less Than 5
Less Than 5
Less Than 5
Corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate
Yes
*** *********** ******* **- *** **, ****. ******** ****** ** ********** ***** ** *** ****. *******, ***** ******. **** ******, ****** ******, ******* ******, *** **** *** ****. **** ***** * **** ** ** *** ******* *** **** *********. ** ****** **** **** **** ****** ** **** ****. *****, ******* ***** * **** ** *** *** *********. ***** ** **** **, **** ******* **** **** ** **. ********** ******* **** **** ******
Corlanor Patent 1 Patent 2 Patent 3 Patent 4
******* ******* ******* ******* *******
***** ****** ******* ******* ******* *******
**** ****** ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ ********* ***** **, **** ******* **** ****** **** ********
***** ****** *** \ *** ***** **, **** ******* ******** ******** ** *** **, ****
**** ****** *** \ *** ***** **, **** ******* ******** ******** ** *** *, ****
  1. *** *, **** : ******* ******** ***** ***** **'* **** ** ****** ** *** *******.
  2. *** *, **** : ***** ****** ******** ***** ***** **'* **** ** ****** ** *** *******.
  3. *** **, **** : **** ****** *** ****** ****** (******, ******) ******** ***** ***** **'* **** ** ****** ** *** *******.
  4. *** **, **** : ******* (*******) ****** ******** ***** ***** **'* **** ** ****** ** *** *******.
  5. *** **, **** : *** **** ******** ***** ***** **'* **** ** ****** ** *** *******.
  6. *** **, **** : ***** ***** * **** ******* ******* ** *** *******.
  7. *** **, **** : ***** ***** * **** ******* ***** ****** ** *** *******.
  8. *** **, **** : ***** ***** * **** ******* **** ****** ** *** *******.
  9. *** **, **** : ***** ***** * **** ******* ****** ****** *** ******* (*******) ****** ** *** *******.
  10. *** **, **** : ***** ***** * **** ******* *** **** ** *** *******.
  11. *** *, **** : ******* ******** ***** ***** **'* **** ** ****** ** *** *******.
  12. *** **, **** : ***** ***** * **** ******* ******* ** *** ******* '*** '*** '*** *** '***.
  13. *** **, **** : ******* (*******) ****** *** ***** **** ******* *** ********** **** ************ ** ****** **. '*** '*** '*** *** '***.
  14. *** *, **** : ******* **** ** ** *** ***** ******* *****.
  15. *** **, **** : ***** ******* **** *** **** ***** ******* *****.
  16. *** *, **** : ***** ******* **** **** ****** ** ******* ***** ** **********.
  17. *** **, **** : ***** *** ***** **** ******* *** ********** **** ************ ** ****** **. '*** '*** '*** *** '***.
  18. *** *, **** : ****** *** ***** **** ******* *** ********** **** ************ ** ****** **. '*** '*** '*** *** '***.
  19. *** **, **** : ***** ******* **** ******* ***** ******* *****.
  20. *** *, **** : ******* (*******) ****** *** *** ******** (******* ************).

Corlanor - (5MG/5ML)

Ivabradine Hydrochloride None
5MG/5ML
Less Than $1000 mn
None None
None None
None None
Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: • To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. • For the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients ages 6 months and older.
Yes
Corlanor Patent 1 Patent 2 Patent 3 Patent 4
*** *********
β-*********** **** ** ********** *************, * ******* *** *** *********** *** ************** ************ ********** ** γ-*********** **** ** ********** *************, * ******* *** *** *********** *** ************** ************ ********** ** γ-*********** **** ** ********** *************, * ******* *** *** *********** *** ************** ************ ********** ** ****-*********** **** ** ********** *************, * ******* *** *** *********** *** ************** ************ ********** **

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.